

Your brand of pravastatin is changing

Clinect is your new brand

Between 1 December 2023 and 1 May 2024, your brand of pravastatin will be changing from Mylan or Viatris Pravastatin to Clinect Pravastatin.

What's changed?

Your brand of pravastatin will be changing from Mylan or Viatris Pravastatin to Clinect Pravastatin. Your tablet will look different and the packaging will change, but the medicine will work the same.

Key differences:

- Shape - the new tablets are round
- Colour - the 40 mg tablets are green
- Lettering - the Clinect tablets have APO on one side and PRA with the strength on the other (20 or 40)

Mylan / Viatris (Current)

20 mg



40 mg



Clinect (New)



Not actual size

Clinect Pravastatin works the same way

Clinect Pravastatin contains the same active ingredient in the same quantities as the Mylan and Viatris tablets. It will work in your body the same way.

Medsafe has assessed the Clinect brand for safety, effectiveness, and quality. It meets the same standards as the Mylan and Viatris brands. It is approved for use in New Zealand.

Why is this happening?

Pharmac runs an annual tender on many of the medicines we fund. This tender gives suppliers an opportunity to offer already funded products for better, more competitive prices. The savings we make through the tender process frees up money so we can fund new treatments for people.

This brand change is helping us fund more medicines for better health outcomes for all New Zealanders.

Questions?

Talk to your pharmacist or the person who prescribes your pravastatin.

Visit Pharmac's website www.pharmac.govt.nz/pravastatin